Q-omics provides the consensus-scored METRNL profile across patient tissues and cancer cell-line models. METRNL expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, METRNL is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, METRNL RNA expression shows 16,564 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UVM, KIRC, and THYM as cancer lineages where METRNL shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for METRNL — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes METRNL survival associations across molecular data types. METRNL RNA expression shows survival associations in the most cancer types (21), followed by mutation status (2) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible METRNL RNA expression–survival associations across cancer types. High METRNL expression shows unfavorable associations in UVM, KIRC, LGG, KIRP, ACC and PAAD. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for METRNL RNA expression.
This table summarizes METRNL tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for METRNL. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. METRNL shows lower tumor expression in KIRC, LUAD, COAD, UCEC and KIRP and higher tumor expression in CHOL. The KIRC box plot shows higher METRNL RNA expression in normal versus tumor tissue (log2 FC = −1.270, t-test p < 0.001).
This table shows molecular features associated with METRNL in patient tissues and cancer cell lines. In patient samples, METRNL shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, METRNL RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BONE.
